Elypta, a Swedish diagnostics firm aiming to commercialize the primary metabolism-based liquid biopsy for early detection of any most cancers, has raised $21 million in a collection A financing spherical led by Bonnier Ventures.
“The collection A is a pivotal second for Elypta because it totally funds the event of our two main indications,” stated Karl Bergman, CEO at Elypta.
The corporate will use the capital to develop and validate blood and urine exams for multi-cancer early detection (MCED) in adults with no signs of most cancers and for detection of recurrence in kidney most cancers sufferers. The exams are based mostly on the profiling of human glycosaminoglycans – often known as the GAGome – as biomarkers of most cancers metabolism, an method pioneered by Elypta based mostly on analysis carried out at Chalmers College of Know-how by founders Francesco Gatto and Jens Nielsen.
“Our MCED take a look at has the potential to tremendously enhance the share of cancers detected on the earliest levels when therapy might imply a treatment in addition to being less expensive,” Gatto stated.
“Detecting stage I most cancers is the important thing problem right here, and whereas different MCED exams based mostly on cell free DNA wrestle to search out most cancers at this early stage, metabolism-based biomarkers might actually make a distinction.”
Bonnier Ventures led the spherical and had been joined by present firms akin to Wallenberg Funding’s enterprise capital arm Navigare Ventures, Industrifonden, Norrsken VC, Nina Capital, Chalmers Ventures and Hillclimber. Locust Stroll served as transaction advisor to Elypta.
“Bonnier Ventures is proud to assist Elypta’s glorious crew of their mission to scale back most cancers mortality, says Sofia Hasselberg, Funding Director at Bonnier Ventures.
“The metabolism-based expertise is exclusive on this area and permits detection of many most cancers varieties previous to signs. As it’s also extra cost-efficient than something now we have seen, we imagine it has nice potential to enhance most cancers outcomes.”
Ongoing research
Elypta at present has two main multicenter research in progress, LEVANTIS-0087A for MCED and AURORAX-0087A, an EU co-funded examine beneath grant settlement No 849251, for kidney most cancers recurrence.
LEVANTIS-0087A is a retrospective examine to validate the diagnostic efficiency of free GAGome-based exams for MCED detection in adults asymptomatic for most cancers with no latest historical past of most cancers. The examine plans to enrol greater than 9,000 individuals.
AURORAX-0087A is a examine to validate the diagnostic efficiency of free GAGome-based exams for the early detection of recurrence after healing intent surgical procedure in sufferers.
Cowl picture: Shutterstock
